News
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results